tbResList Print — LDN low dose naltrexone

Filters: qv=198, qv2=%, rfv=%

Product

LDN low dose naltrexone
Description: <b>Naltrexone</b> is a medication primarily used to treat opioid addiction and alcohol dependence. Some studies suggest that low-dose naltrexone (LDN) may have anti-cancer properties.<br>
LDN has been shown to inhibit the growth of certain types of cancer cells, including breast, lung, and colon cancer cells, in laboratory studies.<br>

Pathway results for Effect on Cancer / Diseased Cells

Functional Outcomes ⓘ

OS↑, 2,   TumVol↓, 1,   Weight↑, 1,  
Total Targets: 3

Pathway results for Effect on Normal Cells

Total Targets: 0

Research papers

Year Title Authors PMID Link Flag
2017The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone ProtocolBurton M BerksonPMC6142095https://pmc.ncbi.nlm.nih.gov/articles/PMC6142095/0
2009Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases Burton M Berkson 20042414https://pubmed.ncbi.nlm.nih.gov/20042414/0
2006The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocolBurton M Berkson 16484716https://pubmed.ncbi.nlm.nih.gov/16484716/0